Every Form 4 that ArriVent BioPharma, Inc. (AVBP) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow AVBP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full AVBP filings page.
ArriVent BioPharma, Inc. director Parsey Merdad received a grant of non-qualified stock options covering 13,562 shares of common stock. The options have an exercise price of $31.74 per share and expire on June 17, 2036.
The shares underlying this option vest on the first anniversary of the June 18, 2026 grant date, subject to his continued service through the vesting date. Following this award, he holds 13,562 derivative securities directly.
ArriVent BioPharma director Kristine Peterson received a new stock option grant. She was awarded a non-qualified option covering 13,562 shares of common stock at an exercise price of $31.74 per share. The option vests on the first anniversary of the grant date, contingent on her continued service, and expires on June 17, 2036. Following this grant, she holds 13,562 derivative securities directly from this award.
ArriVent BioPharma, Inc. director John Hohneker received a grant of non-qualified stock options covering 13,562 shares of common stock. The options have an exercise price of $31.74 per share, expire on June 17, 2036, and vest on the first anniversary of the June 18, 2026 grant date, subject to continued service.
ArriVent BioPharma director Chris Nolet received a grant of non-qualified stock options covering 13,562 shares of common stock. The options have an exercise price of $31.74 per share and expire on June 17, 2036. The underlying shares vest on the first anniversary of the June 18, 2026 grant date, conditioned on continued service.
ArriVent BioPharma’s Chief Operating Officer, Robin LaChapelle, reported receiving a stock option award covering 130,000 shares of common stock. The option, granted on February 2, 2026, has an exercise price of $22.67 per share and expires on February 2, 2036.
The award vests as to 25% of the underlying shares on February 2, 2027. The remaining shares vest in 36 equal monthly installments thereafter, conditioned on LaChapelle’s continued service with the company through each vesting date.
ArriVent BioPharma, Inc. reported that director and President of R&D Stuart Lutzker received a grant of 150,000 stock options to purchase common stock at an exercise price of $22.67 per share on February 2, 2026. These options expire on February 2, 2036.
The options vest 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments after that date, conditioned on Lutzker’s continued service through each vesting date. Following this grant, he beneficially owns 150,000 derivative securities directly.
ArriVent BioPharma’s Chief Financial Officer Winston Kung received a stock option grant reported on this Form 4. On February 2, 2026, he was awarded an option to purchase 140,000 shares of common stock at an exercise price of $22.67 per share.
The option vests over time, with 25% of the underlying shares vesting on February 2, 2027. The remaining shares vest in 36 equal monthly installments thereafter, conditioned on his continued service with the company through each vesting date. The option expires on February 2, 2036.
ArriVent BioPharma’s President and CEO, Zhengbin Yao, reported a new stock option grant. On February 2, 2026, he received an option to purchase 550,000 shares of common stock at an exercise price of $22.67 per share.
According to the filing, 25% of the option vests on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments thereafter, contingent on his continued service. Following this grant, he beneficially owns 550,000 derivative securities directly.
ArriVent BioPharma’s General Counsel, James Paul Kastenmayer, received a stock option grant reported on a Form 4. He was awarded options covering 130,000 shares of common stock at an exercise price of $22.67 per share.
The option was granted on February 2, 2026. The underlying shares vest 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments after that date, conditioned on his continued service. Following this grant, he beneficially owns 130,000 stock options directly.
Hillhouse-affiliated investment entities reduced their stake in ArriVent BioPharma, Inc. A group of vehicles managed by Hillhouse Investment Management and HHLR Advisors reported selling 555,555 shares of ArriVent common stock on December 10, 2025 at $23.37 per share.
After this sale, the reporting group indirectly held 3,929,117 ArriVent shares through entities including HACF, L.P., VSUM VI Holdings Limited, VSUM VIII Holdings Limited and ARVT Holdings Limited. Hillhouse Investment Management, Ltd. and HHLR Advisors, Ltd. filed jointly as 10% owners and expressly disclaim beneficial ownership beyond their pecuniary interests.